Welcome to our dedicated page for China Sxt Pharmaceuticals SEC filings (Ticker: SXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The China SXT Pharmaceuticals, Inc. (SXTC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. China SXT is a specialty pharmaceutical company focused on Traditional Chinese Medicine Pieces (TCMPs) and Traditional Chinese Medicine Homologous Supplements (TCMHS), with operations based in Taizhou, Jiangsu, China and revenue generated from the People’s Republic of China, as described in its public documents.
China SXT files annual reports on Form 20-F and current reports on Form 6-K, along with registration statements such as Form F-3 for securities offerings. For example, a Form 6-K details the company’s 2025 special meeting of shareholders and the approval of a dual-class share structure, creating Class B Ordinary Shares with fifty votes per share and re-designating existing ordinary shares as Class A Ordinary Shares. Other filings reference the use of a shelf registration statement on Form F-3 for a registered direct offering of Class A ordinary shares (or pre-funded warrants in lieu thereof).
Through this page, users can review how China SXT reports changes in its capital structure, including share consolidations and the adoption of amended and restated memorandum and articles of association, as well as documents related to special shareholder meetings. Real-time updates from the SEC’s EDGAR system are combined with AI-powered summaries that explain the key points of lengthy filings, helping readers understand the implications of forms such as 20-F, 6-K, and F-3 without reading every page.
Investors and researchers can use the SXTC filings page to examine the company’s governance arrangements, voting rights, listing-related disclosures, and details of registered offerings, all as presented in its official SEC submissions.